Investors
- Board of Directors
- Board Meeting
- AGM Notice
- EGM Notice
- Closure Of Trading Window
- Related Party Transactions
- Share Holding Patterns
- Quarterly Results
- Annual Report
- Annual Return
- Secretarial Compliance
- Disclosure U/r 30
- Voting Results
- Newspaper Publications
- Insider Trading Code
- Investors-2
Mail to: companysec@indswift.com[Email id of designated official for the purpose of grievance redressal]
UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 31ST DECEMBER, 2003 |
|||||
|---|---|---|---|---|---|
(RS. IN LACS) |
|||||
PARTICULARS |
For the quarter ended 31.12.2003 (Provisional) |
For the quarter ended 31.12.2002 (Provisional) |
For theNine months ended 31.12.2003 (Provisional) |
For the Nine months ended 31.12.2002 (Provisional) |
For the year ended 31.03.2003 (Audited) |
| SALES | 5334.33 |
4632.12 |
15398.91 |
13540.27 |
17828.63 |
| Others Income | 42.67 |
29.79 |
63.11 |
63.29 |
86.00 |
| TOTAL INCOME | 5377.00 |
4661.91 |
15462.02 |
13603.56 |
17914.63 |
| Total Expenditure | 4802.67 |
4136.10 |
13884.68 |
12261.00 |
16232.57 |
| Decrease in Stock in trade | -327.82 |
-649.28 |
-606.38 |
-584.07 |
-734.49 |
| Consumption of material | 4403.19 |
4189.34 |
12422.24 |
11068.63 |
14321.04 |
| Staff Cost | 178.28 |
147.50 |
488.97 |
425.20 |
596.86 |
| Other expenditure | 549.02 |
448.54 |
1579.85 |
1351.24 |
2049.16 |
| Interest | 139.72 |
176.56 |
425.40 |
372.55 |
444.10 |
| Depreciation | 25.95 |
20.90 |
71.40 |
59.66 |
78.54 |
| PROFIT BEFORE TAX | 408.66 |
328.35 |
1080.54 |
910.35 |
1159.42 |
| Provision for Tax | 30.65 |
24.63 |
82.30 |
71.33 |
84.36 |
| Provision for Deferred Tax | 60.99 |
4.50 |
70.65 |
30.68 |
55.84 |
| Income Tax for the previous year | |||||
| Net Profit | 317.02 |
299.22 |
927.59 |
808.34 |
1019.22 |
| Paid up Equity Share Capital | 439.50 |
439.50 |
439.50 |
439.50 |
439.50 |
| Reserves Excluding Revaluation Reserves | 21.11 |
18.39 |
4316.16 |
||
| EPS - Rs | 439.50 |
6.81 |
2884510 |
||
NOTES: |
|||||
| 1. During the quarter under review, the turnover and the profit before tax of the company has increased by over 15% and 25% respectively as compared to the corresponding quarter of the previous year. 2. The Company has been granted a US Patent for “Controlled Release Macrolide Pharmaceutical Formulations” for one of its products, the market size of which is US $ 300 million. 3. As a part of its expansion plans, the company is setting up a formulation manufacturing facility at Baddi (H.P). 4. The company has received 5 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 31st December, 2003. 5. The Company is exclusively in the Pharmaceutical business segment. 6. The above financial results were taken on record by the Board at its meeting held on 21st January, 2004. |
|||||
On behalf of the
Board |
|||||
Dated: 21.01.2004 |
(Gopal Munjal) |
||||
Place: Chandigarh |
Chairman |
||||